Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ernst A et al. | Lung abcess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: case report and review. | 1998 | Transplantation | pmid:9448158 |
Cavaillé-Coll MW and Elashoff MR | Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. | 1998 | Transplantation | pmid:9448161 |
O'Grady J | C(2) monitoring: out of the blocks but with some way to go! | 2004 | Transplantation | pmid:15201659 |
Fung JJ | Tacrolimus and transplantation: a decade in review. | 2004 | Transplantation | pmid:15201685 |
Tydén G et al. | Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. | 2007 | Transplantation | pmid:17496528 |
van Hooff JP et al. | A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. | 2003 | Transplantation | pmid:12829890 |
Miroux C et al. | In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. | 2012 | Transplantation | pmid:22743548 |
Heffron TG et al. | Pediatric liver transplantation with daclizumab induction. | 2003 | Transplantation | pmid:12829908 |
Gathogo E et al. | Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. | 2016 | Transplantation | pmid:26413990 |
Papadopoulos-Köhn A et al. | Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. | 2015 | Transplantation | pmid:25208324 |
Ericzon BG et al. | The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. | 1992 | Transplantation | pmid:1376501 |
Ciancio G et al. | Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. | 1997 | Transplantation | pmid:9075856 |
Watanabe M et al. | Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. | 2013 | Transplantation | pmid:23860082 |
Starzl TE et al. | Hepatotrophic effects of FK506 in dogs. | 1991 | Transplantation | pmid:1702912 |
Yamamoto S et al. | FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. | 2004 | Transplantation | pmid:15591950 |
Nashan B et al. | Clinical validation studies of Neoral C(2) monitoring: a review. | 2002 | Transplantation | pmid:12023607 |
Camirand G et al. | Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. | 2001 | Transplantation | pmid:11468532 |
Squifflet JP et al. | Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. | 2001 | Transplantation | pmid:11468536 |
Araki M et al. | Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. | 2006 | Transplantation | pmid:16477217 |
Gallon L et al. | ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. | 2006 | Transplantation | pmid:16477235 |
Niioka T et al. | Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. | 2012 | Transplantation | pmid:23073468 |
Shaffer D et al. | Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). | 1995 | Transplantation | pmid:7535958 |
Jain A et al. | Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. | 2001 | Transplantation | pmid:11374410 |
Neumann UP et al. | Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. | 2001 | Transplantation | pmid:11374419 |
Chan K et al. | Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. | 2011 | Transplantation | pmid:21836540 |
Ahsan N et al. | Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. | 2001 | Transplantation | pmid:11477347 |
Andries S et al. | Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. | 2001 | Transplantation | pmid:11477351 |
Wannhoff A et al. | Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. | 2014 | Transplantation | pmid:25022236 |
Sureshkumar KK and Chopra B | In search of an optimal induction agent in kidney transplantation. | 2014 | Transplantation | pmid:24978038 |
Taler SJ et al. | Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. | 1996 | Transplantation | pmid:8970613 |
Srinivas TR et al. | The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. | 2005 | Transplantation | pmid:16251854 |
Roelen DL et al. | Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. | 1993 | Transplantation | pmid:7687397 |
Yamani MH et al. | The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. | 2000 | Transplantation | pmid:10868634 |
Blakolmer K et al. | Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. | 2000 | Transplantation | pmid:10868635 |
Verleden GM et al. | Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. | 2002 | Transplantation | pmid:12131703 |
Johnson C et al. | Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. | 2000 | Transplantation | pmid:10755536 |
Miller J et al. | Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. | 2000 | Transplantation | pmid:10755543 |
Ochiai T et al. | Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. | 1987 | Transplantation | pmid:2447689 |
Inamura N et al. | Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. | 1988 | Transplantation | pmid:2447690 |
Shapiro R et al. | Tacrolimus in pediatric renal transplantation. | 1996 | Transplantation | pmid:8990356 |
Gillard P et al. | Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. | 2014 | Transplantation | pmid:24770614 |
Brito-Costa A et al. | Factors Associated With Changes in Body Composition Shortly After Orthotopic Liver Transplantation: The Potential Influence of Immunosuppressive Agents. | 2016 | Transplantation | pmid:27136260 |
Ko S et al. | The pharmacokinetic benefits of newly developed liposome-incorporated FK506. | 1994 | Transplantation | pmid:7526494 |
Bazerbachi F et al. | Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. | 2013 | Transplantation | pmid:23183776 |
Dieterle CD et al. | Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. | 2004 | Transplantation | pmid:15239622 |
Inomata Y et al. | The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. | 1996 | Transplantation | pmid:8600632 |
Tricot L et al. | Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. | 2005 | Transplantation | pmid:16371923 |
Veenhof H et al. | Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. | 2017 | Transplantation | pmid:27906832 |
MacPhee IA and Holt DW | A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. | 2008 | Transplantation | pmid:18212618 |
Tourret J et al. | Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. | 2017 | Transplantation | pmid:27681266 |